Oramed wins Chinese patent for oral core technology

Oramed ($ORMP), the Jerusalem-based developer of two oral diabetes products in clinical trials, landed approval for a Chinese patent of its core technology from the country's State Intellectual Property Office. The patent--Oramed's eighth--covers the company's methods and compositions for the oral administration of proteins. New Zealand and South Africa offices also granted patents, and Oramed has 27 more patents pending. Oramed has its orally ingestible insulin pill in Phase II and recently submitted a pre-IND for its oral exenatide capsule for Type 2 diabetes. Release

Suggested Articles

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.

Researchers at Johns Hopkins have changed the structure of a new cancer drug to allow it to more easily pass the blood-brain barrier, giving it access to…

Medtronic’s world-first FDA-approved hybrid closed-loop insulin delivery system might soon face competition, as T1D Exchange has pledged to invest in the…